Real-World Evidence for Oncology Innovation in Europe

Real-world evidence (RWE) is becoming an indispensable tool for pharma companies. The availability of digital health tools, electronic health records (EHRs) and advances in data analytics have facilitated the large-scale collection of real-world data (RWD), enabling a wealth of insights into patient outcomes and clinical effectiveness and safety of medicines beyond clinical trials.

This Financial Times webinar, in partnership with Flatiron Health, will bring together global biopharma companies, health regulators, health technology assessors, and other industry experts to explore the evolving landscape for real-world evidence (RWE) in Europe, and how the regional and global evidence base can be improved and harmonised to revolutionise healthcare decision-making, drug development and patient care.

The Landscape in Europe

How is the RWE/RWD landscape in Europe evolving? Where are the evidence gaps and how could the health information infrastructure be improved?

Opportunities For Pharma

How could a more unified, harmonised approach to RWD/RWE across markets, through common data models, unlock new efficiencies and new research opportunities for pharma?

Challenges & Limitations

What are the challenges in creating multinational real-world data (RWD) applicable across multiple markets?  What are the limitations of data transportability, and how can robustness, reliability of the evidence be assured?

FT Live Digital Dialogues - fully digital 50 minute event experiences delivering maximum engagement. Live webinars provide unique opportunities to engage global senior audiences. All access, digital passes include access to all the live sessions PLUS all sessions on demand for 30 days. Join the conversation.

© Financial Times Live

FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice